Fulgent Genetics Soars 16.41% on Strong Q2 Earnings

Fulgent Genetics' stock surged 16.41% in pre-market trading on August 1, 2025, driven by strong financial performance and strategic initiatives.

Fulgent Genetics reported robust financial results for the second quarter of 2025, with total revenue reaching $81.8 million. Core revenue, a key metric for the company, grew by 16% year-over-year to $81.7 million, reflecting strong demand for its genetic testing services. The company also raised its full-year 2025 core revenue guidance to $320 million, indicating confidence in its future performance.

In addition to revenue growth, Fulgent Genetics demonstrated operational efficiency by improving its gross margin from 37% to 42% year-over-year for the three months ended June 30, 2025. This improvement was driven by increased revenue and cost management efforts, highlighting the company's ability to enhance profitability.

Despite the positive financial results, the company reported a GAAP loss, which was attributed to higher operating expenses and impairment charges. However, the strong revenue growth and improved gross margin suggest that Fulgent Genetics is on track to achieve its financial goals for the year.